abstract |
FIELD: medicine.SUBSTANCE: group of inventions relates to the field of medicine, in particular, to the use of a combination or composition of obinutuzumab with an CD79b antibody-drug conjugate, which is an anti-CD79b-MC-vc-PAB-MMAE, for the treatment of cancer, wherein the anti-CD79b antibody in said conjugate is huMA79b.v28 comprising a light chain variable domain of SEQ ID NO: 69 and the heavy chain variable domain of SEQ ID NO: 70. In one embodiment, the cancer is a CD20 expressing cancer, in particular lymphoma or lymphocytic leukemia.EFFECT: inventions provide an enhanced antiproliferative effect in the treatment of cancer.6 cl, 12 dwg, 6 tbl, 2 ex |